Annals of oncology : official journal of the European Society for Medical Oncology
Journal
Overview
publication venue for
-
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
2018
-
Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.
2017
-
Second cancers complicating Hodgkin's disease.
1996
-
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.
2024
-
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030..
34.
2023
-
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
2023
-
Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations..
34.
2022
-
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas..
33.
2022
-
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial..
33.
2022
-
Deciphering radiological stable disease to immune checkpoint inhibitors..
33.
2022
-
Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing..
33.
2022
-
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial..
32.
2021
-
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial..
32.
2021
-
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies..
32.
2021
-
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆..
31.
2020
-
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker..
31.
2020
-
COVID-19 in patients with lung cancer..
31.
2020
-
Characterization of on-target adverse events caused by TRK inhibitor therapy..
31.
2020
-
Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients..
31.
2020
-
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas..
31.
2020
-
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer..
31.
2019
-
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†..
30.
2019
-
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals..
30.
2019
-
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer..
30.
2019
-
Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group..
30.
2019
-
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry..
30.
2019
-
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages..
30.
2019
-
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer..
30.
2019
-
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up..
30.
2019
-
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib..
30.
2019
-
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001..
30.
2019
-
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial..
30.
2019
-
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium..
30.
2019
-
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy..
30.
2019
-
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer..
29.
2018
-
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial..
29.
2018
-
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers..
29.
2018
-
Different menopausal hormone regimens and risk of breast cancer..
29.
2018
-
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)..
29.
2018
-
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer..
29.
2018
-
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma..
29.
2018
-
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected..
29.
2018
-
Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma..
29.
2018
-
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases..
29.
2018
-
Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer..
29.
2018
-
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)..
29.
2018
-
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study..
29.
2018
-
Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013..
28.
2017
-
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era..
28.
2017
-
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)..
28.
2017
-
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma..
28.
2017
-
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy..
28.
2017
-
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)..
28.
2017
-
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer..
28.
2017
-
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium..
28.
2017
-
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study..
28.
2017
-
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide..
28.
2017
-
Oncologist use and perception of large panel next-generation tumor sequencing..
28.
2017
-
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC..
28.
2017
-
Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma..
28.
2017
-
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States..
28.
2017
-
Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape..
28.
2017
-
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors..
28.
2017
-
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)..
28.
2017
-
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer..
28.
2017
-
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer..
28.
2017
-
Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers..
28.
2017
-
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma..
27.
2016
-
Consensus on precision medicine for metastatic cancers: a report from the MAP conference..
27.
2016
-
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015..
30.
2016
-
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment..
27.
2016
-
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers..
27.
2016
-
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma..
27.
2016
-
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study..
27.
2016
-
Neoadjuvant chemotherapy in ovarian cancer revisited..
27 Suppl 1.
2016
-
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial..
27.
2016
-
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer..
27.
2016
-
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel..
27.
2015
-
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)..
27.
2015
-
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials..
27.
2015
-
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL..
27.
2015
-
A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers..
27.
2015
-
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†..
26.
2015
-
Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram..
26.
2015
-
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors..
26.
2015
-
Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma..
26.
2015
-
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer..
26.
2015
-
Incidence and determinants of 1-month mortality after cancer-directed surgery..
26.
2014
-
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment..
26.
2014
-
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer..
25.
2014
-
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†..
25.
2014
-
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies..
25.
2014
-
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle..
25.
2014
-
Survival of women with inflammatory breast cancer: a large population-based study..
25.
2014
-
Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC)..
25.
2014
-
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC..
25.
2014
-
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial..
25.
2014
-
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing..
25.
2014
-
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies..
25.
2014
-
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival..
25.
2013
-
Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma..
25.
2013
-
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)..
24.
2013
-
Ulcer, gastric surgery and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)..
24.
2013
-
Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host..
24.
2013
-
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer..
24.
2013
-
Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial..
24.
2013
-
Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients..
24.
2013
-
Efficacy of multimodal exercise-based rehabilitation on physical activity, cardiorespiratory fitness, and patient-reported outcomes in cancer survivors: a randomized, controlled trial..
24.
2013
-
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials..
24.
2013
-
Predictors of recovery of ovarian function during aromatase inhibitor therapy..
24.
2013
-
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer..
24.
2013
-
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study..
24.
2013
-
Attitudes of patients with metastatic breast cancer toward research biopsies..
24.
2013
-
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer..
24.
2013
-
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse..
24.
2013
-
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma..
24.
2012
-
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy..
24.
2012
-
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices..
24.
2012
-
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors..
24.
2012
-
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer..
24.
2012
-
Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4)..
23.
2012
-
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis..
23.
2012
-
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer..
23.
2012
-
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness..
23.
2012
-
Extending the clinical research network approach to all of healthcare..
22 Suppl 7.
2011
-
Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival..
23.
2011
-
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy..
23.
2011
-
Distribution of metastatic sites in renal cell carcinoma: a population-based analysis..
23.
2011
-
A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer..
23.
2011
-
Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors..
23.
2011
-
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group..
23.
2011
-
Histology and outcomes of newly detected lung lesions in melanoma patients..
23.
2011
-
Lung cancer physicians' referral practices for palliative care consultation..
23.
2011
-
Identifying factors that impact survival among women with inflammatory breast cancer..
23.
2011
-
Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion..
23.
2011
-
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840..
23.
2011
-
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy..
23.
2011
-
Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience..
23.
2011
-
Toxicity burden score: a novel approach to summarize multiple toxic effects..
23.
2011
-
Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays..
22.
2011
-
Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification..
23.
2011
-
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer..
22.
2011
-
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?.
22.
2011
-
GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients..
22.
2011
-
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer..
22.
2011
-
Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)..
22.
2011
-
Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods..
22.
2011
-
Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts..
22.
2010
-
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer..
22.
2010
-
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity..
22.
2010
-
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation..
22.
2010
-
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031..
22.
2010
-
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma..
22.
2010
-
Phase I trial of SU14813 in patients with advanced solid malignancies..
22.
2010
-
Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization..
22.
2010
-
Incidence of and survival following brain metastases among women with inflammatory breast cancer..
21.
2010
-
Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors..
21.
2010
-
Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary..
21.
2010
-
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study..
21.
2010
-
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients..
21.
2010
-
Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma..
21.
2010
-
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience..
21.
2009
-
Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma..
21.
2009
-
Race and ethnicity correlate with survival in patients with gastric adenocarcinoma..
21.
2009
-
Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer..
21.
2009
-
Circulating tumor cells in metastatic inflammatory breast cancer..
20.
2009
-
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors..
20.
2009
-
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival..
20.
2009
-
Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer..
20.
2009
-
Expanding the boundaries of clinical practice: building on experience with targeted therapies..
20 Suppl 1.
2009
-
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer..
20.
2009
-
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications..
20.
2009
-
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer..
20.
2009
-
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study..
20.
2009
-
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102..
20.
2009
-
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205..
20.
2009
-
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)..
20.
2009
-
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study..
20.
2008
-
Detection of circulating tumor cells in patients with urothelial cancer..
20.
2008
-
Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer..
20.
2008
-
Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma..
19.
2008
-
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations..
19.
2008
-
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors..
19.
2008
-
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies..
19.
2008
-
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17..
19.
2008
-
High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age..
19.
2008
-
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207..
19.
2008
-
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies..
19.
2008
-
Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy..
19.
2007
-
Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis..
18.
2007
-
Systemic chemotherapy does not increase the risk of gastrointestinal perforation..
18.
2007
-
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma..
19.
2007
-
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma..
18.
2007
-
An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b..
18.
2007
-
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma..
18.
2007
-
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804..
18.
2007
-
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer..
18.
2007
-
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer..
18.
2007
-
Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer..
18.
2007
-
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer..
18.
2007
-
Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies..
18.
2006
-
Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment..
17.
2006
-
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group..
17.
2006
-
Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975..
17.
2006
-
Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group..
17.
2006
-
A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer..
17.
2006
-
Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population..
17.
2006
-
Measuring tumor response and shape change on CT: esophageal cancer as a paradigm..
17.
2006
-
Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer..
17.
2006
-
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas..
17.
2006
-
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits..
17.
2006
-
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase..
17.
2005
-
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer..
16.
2005
-
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group..
16.
2005
-
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate..
16.
2005
-
FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases..
16.
2005
-
CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients..
15.
2004
-
Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma..
15.
2004
-
Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer..
15.
2004
-
Recommendations for a Global Core Curriculum in Medical Oncology..
15.
2004
-
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway..
15.
2004
-
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide..
15.
2004
-
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma..
15.
2004
-
Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma..
15.
2004
-
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial..
15.
2004
-
A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer..
15.
2004
-
NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen..
15.
2004
-
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors..
15.
2004
-
Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer..
15.
2004
-
Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer..
15.
2004
-
Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver..
15.
2004
-
Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis..
15.
2004
-
Twenty-five years of treating advanced NSCLC: what have we achieved?.
15 Suppl 4.
2004
-
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration..
14.
2003
-
Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity..
14.
2003
-
Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923)..
14.
2003
-
Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma..
13.
2002
-
Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer..
13.
2002
-
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan..
13.
2002
-
Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy..
13.
2002
-
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer..
13.
2002
-
Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma..
13.
2002
-
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer..
13.
2002
-
A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients..
12.
2001
-
Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study..
12.
2001
-
Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients..
12.
2001
-
A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma..
12.
2001
-
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients..
12.
2001
-
Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients..
11.
2000
-
Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract..
11.
2000
-
Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients..
11.
2000
-
The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why..
11.
2000
-
Caelyx in malignant mesothelioma: a phase II EORTC study..
11.
2000
-
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer..
11.
2000
-
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients..
11.
2000
-
A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma..
11.
2000
-
A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors..
11.
2000
-
Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy..
10.
1999
-
Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy..
10.
1999
-
Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder..
10.
1999
-
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma..
10.
1999
-
Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors..
10.
1999
-
Is primary CNS lymphoma really becoming more common? A population-based study of incidence, clinicopathological features and outcomes in Alberta from 1975 to 1996..
10.
1999
-
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer..
9.
1998
-
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study..
9.
1998
-
A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer..
9.
1998
-
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B..
9.
1998
-
A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study..
8.
1997
-
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer..
8.
1997
-
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer..
8.
1997
-
Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC)..
8.
1997
-
Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study..
8.
1997
-
Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy..
8.
1997
-
Initial chemotherapy for primary resectable large-cell lymphoma of the stomach..
8.
1997
-
Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma..
7.
1996
-
The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study..
7.
1996
-
Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues..
7.
1996
-
Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group..
7.
1996
-
A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial..
7.
1996
-
Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients..
7.
1996
-
Gene therapy--the challenge for the future..
7 Suppl 2.
1996
-
Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients..
6.
1995
-
Prognostic relevance of P-glycoprotein expression in breast cancer..
6.
1995
-
Sources of anticipatory emotional distress in women receiving chemotherapy for breast cancer..
6.
1995
-
Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer..
6.
1995
-
A matched control study of familial epithelial ovarian cancer: patient characteristics, response to chemotherapy and outcome..
6.
1995
-
P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder..
5.
1994
-
Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer..
5 Suppl 6.
1994
-
A phase II study of DuP 937 (Teloxantrone) in metastatic malignant melanoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCICCTG)..
4.
1993
-
Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors..
4.
1993
-
Carboplatin and 5-fluorouracil in poor performance status patients with advanced urothelial cancer..
4.
1993
-
Recombinant tumor necrosis factor for superficial bladder tumors..
3.
1992
-
Letter to the editor concerning 'Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis'..
26.
2015
-
Atypical femur fractures associated with use of bisphosphonates and denosumab..
26.
2015
-
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms..
24.
2013
-
Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?.
24.
2013
-
Specific PPAR gamma agonists may have different effects on cancer incidence..
24.
2013
-
Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis..
20.
2009
-
Clubbing, arthralgia and haemoptysis in a patient with metastatic carcinoma of the breast..
7.
1996
-
Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells.
2019
-
Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells.
2018
-
Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes.
2017
-
Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy.
2015
-
Capecitabine dosing is not yet optimized for breast cancer.
2010
-
Irinotecan chemotherapy associated with transient dysarthria and aphasia.
2004
-
Carboplatin and etoposide in metastatic breast cancer.
1995
-
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
2017
-
New insights into pancreatic cancer biology.
2012
-
Expanding the nanotherapeutic toolbox for non-small-cell lung cancer..
32.
2020
-
Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102..
31.
2020
-
ESR1 and endocrine therapy resistance: more than just mutations..
29.
2018
-
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer..
28.
2017
-
PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?.
28.
2017
-
Cabozantinib: targeted therapy back to the future?.
28.
2017
-
Atypical autoimmune adverse effects with checkpoint blockade therapies..
28.
2017
-
Better use of immune checkpoint inhibition: Treating higher risk patients and examining neurologic toxicity..
28.
2017
-
Prioritizing precision medicine for prostate cancer..
26.
2015
-
Boning up on prognostic factors in advanced renal cell carcinoma..
22.
2011
-
Endocrine resistance in breast cancer: what really matters?.
18.
2007
-
Matrix metalloproteinase inhibitors: how can we optimize their development?.
12.
2001
-
Hormone refractory metastatic prostate cancer..
3.
1992
-
Quality of cancer clinical trials..
1.
1990
-
Small cell lung cancer: a slightly less orphan disease after immunotherapy.
2021
-
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
2020
-
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
2018
-
Why has active immunotherapy not worked in lung cancer?
2015
-
Muscle dysfunction in cancer patients.
2014
-
Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis.
2013
-
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.
2012
-
Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.
2012
-
Src as a potential therapeutic target in non-small-cell lung cancer.
2008
-
Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines.
2007
-
HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy.
2005
-
Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
2000
-
Recurrent squamous-cell carcinoma of the head and neck: overview of current therapy and future prospects.
2000
-
p53 and chemosensitivity.
1999
-
Single-agent use of Taxol (paclitaxel) in breast cancer.
1994
-
Combined-modality therapy in the treatment of local-regional esophageal cancer.
1992
-
Identifying patients with NTRK fusion cancer.
2019
-
Identifying patients with NTRK fusion cancer.
2019
-
Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.
2017
-
Chemotherapy remains an essential element of personalized care for persons with lung cancers.
2016
-
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma.
2008
-
Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer.
2008
-
New monoclonal antibodies for non-Hodgkin's lymphoma.
2008
-
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
2007
-
An overview of the status of imaging screening technology for breast cancer.
2004
-
Progress in the development and acquisition of anticancer agents from marine sources.
2003
-
Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy.
1997
-
The treatment of advanced bladder cancer.
1995
-
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.
2021
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)